Abstract: PUB569
Impact of Dapagliflozin on Anemia Status of Patients with CKD
Session Information
Category: CKD (Non-Dialysis)
- 2302 CKD (Non-Dialysis): Clinical, Outcomes, and Trials
Author
- Griveas, Ioannis, Noseleutiko Idryma Metochikou Tameiou Stratou, Athens, Greece
Background
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have demonstrated cardiovascular and renal benefits in patients with type 2 Diabetes Mellitus, Heart Failure, or Chronic Kidney Disease (CKD). At the same time, there are scattered data which support the hypothesis that SGLT2i may increase hematocrit (Hct) and hemoglobin (Hb). The increase in hemoglobin was strongly associated with the cardiorenal benefits of these drugs. Aim of our study was to investigate the impact of a SGLT2i representative such as Dapagliflozin on anemia status of patients with CKD.
Methods
22 stable CKD patients, that were receiving Dapagliflozin , were enrolled in our study for a period of one year. 72 years was the mean age of our patients. 16 patients were diabetic, one had FSGS, one had ischemic nephropathy, one had ΙgΑ nephropathy, 2 patients had membranous nephropathy and one patient with unknown primary cause of CKD. None of our patients was receiving erythropoietin or Fe supplementations. For a period of one year we measured Hct, Hb, GFR, proteinuria in our study group.
Results
After one year period, Hct was significantly increased from 42.06±4.85 to 44.34±4.74 (p<0.05). Hb was also increased from 13.8±1.63 to 14.36.34±1.50, p=0.63. The above notice was combined with decrease of GFR after one year of giving Dapagliflozin (from 38.66±13.92 mils/min to 34.38±11.59 mils/min, p<0.05). At the same time, proteinuria remained stable over the study period (936.28±1371.10 to 864.47±1256.83, p=NS).
Conclusion
Dapagliflozin use was associated with higher Hct levels in patients with CKD. Our study group is small , but represents the whole spectrum of CKD aetiology. More studies with larger populations are needed to confirm our first impression that SGLT2 inhibitors may be considered as an adjunct therapy to reduce anemia incidence in patients with CKD.